Cargando…

AB140. The effectiveness and adverse effects of amoxapine for treatment of retrograde ejaculation

OBJECTIVE: Retrograde ejaculation (RE) is an ejaculation disorder that can cause male infertility. It is defined as a pathological condition in which some or all semen is not emitted despite orgasm. The main cause of RE is believed to be decreased function of the bladder neck due to conditions such...

Descripción completa

Detalles Bibliográficos
Autores principales: Tai, Toshihiro, Nagao, Koichi, Tamura, Koji, Saigo, Rieko, Tanaka, Norie, Kobayashi, Hideyuki, Nakajima, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708670/
http://dx.doi.org/10.3978/j.issn.2223-4683.2015.s140
_version_ 1782409518786805760
author Tai, Toshihiro
Nagao, Koichi
Tamura, Koji
Saigo, Rieko
Tanaka, Norie
Kobayashi, Hideyuki
Nakajima, Koichi
author_facet Tai, Toshihiro
Nagao, Koichi
Tamura, Koji
Saigo, Rieko
Tanaka, Norie
Kobayashi, Hideyuki
Nakajima, Koichi
author_sort Tai, Toshihiro
collection PubMed
description OBJECTIVE: Retrograde ejaculation (RE) is an ejaculation disorder that can cause male infertility. It is defined as a pathological condition in which some or all semen is not emitted despite orgasm. The main cause of RE is believed to be decreased function of the bladder neck due to conditions such as diabetes, pelvic surgery, and drug resistance. Currently imipramine is the drug of choice for treatment of RE, but side effects such as drowsiness sometimes develop. In this controlled clinical study we evaluated the effectiveness and adverse effects of imipramine and amoxapine for treatment of RE. METHODS: Twenty men were randomly assigned to one of two groups. We gave amoxapine to group I and imipramine to group II during the first 2-week period and examined adverse effects and semen volume. After a 1-week washout period, the drugs were switched for a second 2-week period. Mean age was 42.5 years (range, 30-52). Disease duration was 3 months to 5 years (average, 1.6 years). The main causes of RE were diabetes (n=13), surgery for rectal cancer (n=3), and retroperitoneal lymph node dissection for testicular cancer (n=1) (there is some overlapping); cause was unknown in 4 cases. Male infertility was the reason for consultation in 13 cases. The men were provided with a 2.5-cc syringe for self-measurement of semen volume during ejaculation. RESULTS: In 9 cases, sperm was found in urine after orgasm. With amoxapine treatment, 17 (85.0%) men were able to ejaculate. Mild drowsiness was noted in 4 cases. With imipramine treatment, 13 (65.0%) men were able to ejaculate. Mild drowsiness was noted in 3 cases and severe drowsiness in 1 case. ED was observed in 5 patients, but erection hardness was greater than EHS3 after use of PDE5I. All men who reported semen emission with imipramine were also able to ejaculate while receiving amoxapine. Semen volume was significantly greater with amoxapine than with imipramine (P<0.001). The incidence of adverse effects was similar for amoxapine and imipramine. Amoxapine was effective for all men who had positive results with imipramine. CONCLUSIONS: In the treatment of RE, amoxapine was much more effective than imipramine, and equally safe.
format Online
Article
Text
id pubmed-4708670
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-47086702016-01-26 AB140. The effectiveness and adverse effects of amoxapine for treatment of retrograde ejaculation Tai, Toshihiro Nagao, Koichi Tamura, Koji Saigo, Rieko Tanaka, Norie Kobayashi, Hideyuki Nakajima, Koichi Transl Androl Urol Moderated Poster Presentation OBJECTIVE: Retrograde ejaculation (RE) is an ejaculation disorder that can cause male infertility. It is defined as a pathological condition in which some or all semen is not emitted despite orgasm. The main cause of RE is believed to be decreased function of the bladder neck due to conditions such as diabetes, pelvic surgery, and drug resistance. Currently imipramine is the drug of choice for treatment of RE, but side effects such as drowsiness sometimes develop. In this controlled clinical study we evaluated the effectiveness and adverse effects of imipramine and amoxapine for treatment of RE. METHODS: Twenty men were randomly assigned to one of two groups. We gave amoxapine to group I and imipramine to group II during the first 2-week period and examined adverse effects and semen volume. After a 1-week washout period, the drugs were switched for a second 2-week period. Mean age was 42.5 years (range, 30-52). Disease duration was 3 months to 5 years (average, 1.6 years). The main causes of RE were diabetes (n=13), surgery for rectal cancer (n=3), and retroperitoneal lymph node dissection for testicular cancer (n=1) (there is some overlapping); cause was unknown in 4 cases. Male infertility was the reason for consultation in 13 cases. The men were provided with a 2.5-cc syringe for self-measurement of semen volume during ejaculation. RESULTS: In 9 cases, sperm was found in urine after orgasm. With amoxapine treatment, 17 (85.0%) men were able to ejaculate. Mild drowsiness was noted in 4 cases. With imipramine treatment, 13 (65.0%) men were able to ejaculate. Mild drowsiness was noted in 3 cases and severe drowsiness in 1 case. ED was observed in 5 patients, but erection hardness was greater than EHS3 after use of PDE5I. All men who reported semen emission with imipramine were also able to ejaculate while receiving amoxapine. Semen volume was significantly greater with amoxapine than with imipramine (P<0.001). The incidence of adverse effects was similar for amoxapine and imipramine. Amoxapine was effective for all men who had positive results with imipramine. CONCLUSIONS: In the treatment of RE, amoxapine was much more effective than imipramine, and equally safe. AME Publishing Company 2015-08 /pmc/articles/PMC4708670/ http://dx.doi.org/10.3978/j.issn.2223-4683.2015.s140 Text en 2015 Translational Andrology and Urology. All rights reserved.
spellingShingle Moderated Poster Presentation
Tai, Toshihiro
Nagao, Koichi
Tamura, Koji
Saigo, Rieko
Tanaka, Norie
Kobayashi, Hideyuki
Nakajima, Koichi
AB140. The effectiveness and adverse effects of amoxapine for treatment of retrograde ejaculation
title AB140. The effectiveness and adverse effects of amoxapine for treatment of retrograde ejaculation
title_full AB140. The effectiveness and adverse effects of amoxapine for treatment of retrograde ejaculation
title_fullStr AB140. The effectiveness and adverse effects of amoxapine for treatment of retrograde ejaculation
title_full_unstemmed AB140. The effectiveness and adverse effects of amoxapine for treatment of retrograde ejaculation
title_short AB140. The effectiveness and adverse effects of amoxapine for treatment of retrograde ejaculation
title_sort ab140. the effectiveness and adverse effects of amoxapine for treatment of retrograde ejaculation
topic Moderated Poster Presentation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708670/
http://dx.doi.org/10.3978/j.issn.2223-4683.2015.s140
work_keys_str_mv AT taitoshihiro ab140theeffectivenessandadverseeffectsofamoxapinefortreatmentofretrogradeejaculation
AT nagaokoichi ab140theeffectivenessandadverseeffectsofamoxapinefortreatmentofretrogradeejaculation
AT tamurakoji ab140theeffectivenessandadverseeffectsofamoxapinefortreatmentofretrogradeejaculation
AT saigorieko ab140theeffectivenessandadverseeffectsofamoxapinefortreatmentofretrogradeejaculation
AT tanakanorie ab140theeffectivenessandadverseeffectsofamoxapinefortreatmentofretrogradeejaculation
AT kobayashihideyuki ab140theeffectivenessandadverseeffectsofamoxapinefortreatmentofretrogradeejaculation
AT nakajimakoichi ab140theeffectivenessandadverseeffectsofamoxapinefortreatmentofretrogradeejaculation